Stablepharma begins first-in-human trial of “world-first” fridge-free vaccine
The first patient has been dosed in a Phase I trial of Stablepharma’s tetanus-diphtheria vaccine, which does not need to …
Post
-
-
FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS
The US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III …
-
Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) has demonstrated a …
-
A dynamic market: Trends transforming the future of obesity drug development
As obesity levels continue to rise, impacting millions globally, the quest for effective treatments has become a critical public health focus. The …
-
Pacira’s gene therapy shows sustained benefits in trial for knee osteoarthritis
Pacira BioSciences has announced that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), has demonstrated sustained improvements in knee pain, function, …
-
Finerenone continues to impress in diabetic kidney disease
In a recent study conducted by Sankar D Navaneethan and colleagues and published in the International Society of Nephrology, the …
-
Kura doses first subjects in trial of ziftomenib for advanced GIST
Kura Oncology has dosed the first subjects in the open-label Phase Ia/Ib KOMET-015 trial, evaluating the oral investigational menin inhibitor …
-
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in patients …
-
US FDA approves BlackfinBio’s gene therapy trial for hereditary spastic paraplegia
The US Food and Drug Administration has cleared BlackfinBio's investigational new drug (IND) application for a Phase I/II trial of …
-
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
ALX Oncology’s CD47-blocker evorpacept, in combination with MSD’s blockbuster Keytruda (pembrolizumab), has failed to show benefit in two Phase II …
-
Kardium reports strong PFA system trial results
Canada-based Kardium has revealed positive one-year efficacy results on its pulsed field ablation (PFA) device, the Globe PF system, at …
-
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for …
-
MSD reports outcomes from Keytruda combination trial for head and neck cancer
US-based pharmaceutical company MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating resected, locally advanced head …
-
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site …
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and …
